Is Therapeutic Hypothermia for Acute Respiratory Distress Syndrome the Future?

J Intensive Care Med. 2017 Aug;32(7):460-464. doi: 10.1177/0885066617701117. Epub 2017 Mar 27.

Abstract

Introduction: Severe acute respiratory distress syndrome (ARDS) has a high mortality, and there is limited knowledge about management of severe ARDS refractory to standard therapy. Early evidence suggests that therapeutic hypothermia (TH) could be a viable treatment for acute respiratory failure. We present 2 cases where TH was successfully used to manage refractory ARDS on extracorporeal membrane oxygenation (ECMO) and a review of the literature around TH and acute respiratory failure.

Results: We present 2 cases of ARDS secondary to H1N1 influenza and human metapneumovirus. Both patients were treated with the current evidence-based therapy for ARDS. Venovenous ECMO was used in both patients for refractory hypoxemia. Therapeutic hypothermia was applied for 24 hours with improved oxygenation. We did a review of the literature summarizing 38 patients in 10 publications where TH was successfully utilized in the treatment of acute respiratory failure.

Conclusion: Therapeutic hypothermia may be a viable salvage therapy for ARDS refractory to the current evidence-based therapy but needs further evaluation.

Keywords: acute respiratory distress syndrome; extracorporeal membrane oxygenation; refractory hypoxemia; therapeutic hypothermia.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Hypothermia, Induced / methods*
  • Influenza A Virus, H1N1 Subtype
  • Influenza, Human / complications*
  • Influenza, Human / virology
  • Male
  • Metapneumovirus
  • Middle Aged
  • Paramyxoviridae Infections / complications*
  • Paramyxoviridae Infections / virology
  • Respiratory Distress Syndrome / therapy*
  • Respiratory Distress Syndrome / virology
  • Treatment Outcome
  • Young Adult